オプションチェーンは、Treace Medical Conceptsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Treace Medical Conceptsの市場センチメントを評価します。.

Treace Medical Concepts (NASDAQ:TMCI) 株価情報, オプションチェーン

Treace Medical Concepts

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.

Treace Medical Concepts, Inc. - Common Stock

Treace Medical Concepts Inc

WIIM

Alexandria Real Estate shares are trading lower after the company cut its FY25 FFO guidance.

Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) has outperformed the market over the past 5 years by 1.44% on an annualized basis producing an average annual return of 15.73%. Currently, Ford Motor has a market capitalization of $40.12 billion. 
Buying $1000 In F: If an investor had bought $1000 of F stock 5 years ago, it would be worth $2,050.85 today based on a price of $10.09 for F at the time of writing.
<h3>Ford Motor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745939717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Ford Motor Stock In The Last 5 Years

Williams' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) board of directors has approved a regular dividend of $0.50 per share, or $2.00 annualized, on the company's common stock, payable on June 30, 2025, to holders of record at the close of business on June 13, 2025.
This is a 5.3% increase from Williams' 2024 quarterly dividend of $0.4750 per share.

Dividends

Williams Hikes Quarterly Dividend By 5.3% To $0.50/Shr From $0.4750/Shr

General

AREB

American Rebel To Host Strategic Board Meeting And Exclusive Dinner For Investors At Mar-A-Lago

Brown & Brown sharse are trading lower after the company reported a Q1 adjusted EPS miss.

American Tower shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 FFO guidance.

The Liberal Party has won Canada's prime minister election with former central banker Mark Carney keeping his top position, which he was placed in after outgoing Prime Minister Justin Trudeau<a href="https://www.benzinga.com/25/01/42823979/canadas-pm-justin-trudeau-steps-down-amid-internal-conflict-and-tension-over-trump-tariffs"> stepped down in January.</a>
"Who's ready to stand up for Canada with me," Carney said in a speech after winning the election, as <a href="https://www.nbcnews.com/politics/politics-news/canada-election-results-prime-minister-carney-poilievre-rcna203321">reported </a>by NBC News.
Carney also singled out American president Donald Trump in his speech, as Trump has repeated the call for Canada to become the 51st U.S. state.
"President Trump is trying to break us, so that America can own us. That will never, that will never, ever happen."
Carney has had a fast rise in Canadian politics but also enters the key leadership role without ever holding office.
Here are five facts about Carney.
1.&nbsp;Never Held Office:&nbsp;Carney becomes the Liberal Party&#8217;s leader and the&nbsp;<a href="https://www.benzinga.com/25/03/44212152/mark-carney-takes-justin-trudeaus-job-as-canadas-new-pm-ready-to-face-trumps-tariff-threats-i-know-how-to-manage-crises" target="_blank" rel="noreferrer noopener">next Canadian prime minister&nbsp;</a>without holding public office before. The former central banker enters the key leadership role with vast experience in finance, a position that may have helped him win the election.
In his original prime minister acceptance speech, Carney focused heavily on U.S. President&nbsp;Donald Trump, tariffs and a potential trade war between the two North American countries.
&#8220;My government will keep the tariffs on until the Americans show respect,&#8221; Carney previously said. &#8220;In the meantime, we will make sure all the proceeds — all the proceeds from our tariffs — will be used to protect our workers.&#8221; &nbsp;
While the U.S. has paused tariffs on Canada, several retaliatory tariffs put into place by Canada are currently in effect.
Carney also publicly criticized Trump&#8217;s call to annex Canada and make the border country a state.
&#8220;Canada will never ever be part of America, in any way, shape, or form.&#8221;
Carney has also previously&nbsp;<a href="https://nypost.com/2025/03/08/world-news/mark-carney-frontrunner-to-replace-trudeau-as-canadas-pm/" target="_blank" rel="noreferrer noopener">compared&nbsp;</a>Trump to Harry Potter villain Voldemort.
&#8220;When you think about what&#8217;s at stake in these ridiculous, insulting comments of the president, of what we could be, I view this as the sort of Voldemort of comments,&#8221; Carney said.
Before entering politics, Carney&nbsp;<a href="https://www.thecrimson.com/article/2025/3/10/carney-canada-prime-minister/" target="_blank" rel="noreferrer noopener">was&nbsp;</a>the governor of the Bank of Canada (2008 to 2013) and the Bank of England (2013-2020). During his time leading monetary policy, Carney was praised for his handling of the 2008 financial crisis, the U.K.&#8217;s exit from the European Union and the country&#8217;s response to the COVID-19 pandemic. Carney was famously the first non-British person to be governor of the Bank of England.
Along with his roles leading the national banks, Carney also spent 13 years at&nbsp;Goldman Sachs&nbsp;Group Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>).
Read Also:&nbsp;<a href="https://www.benzinga.com/news/25/03/44213871/canadas-next-pm-mark-carney-vows-to-win-trade-war-with-trump-says-americans-should-make-no-mistake" target="_blank" rel="noreferrer noopener">Canada's Next PM Mark Carney Vows To Win Trade War With Trump: ‘Americans Should Make No Mistake'</a>
2.&nbsp;College Goalie: Carney becomes the first graduate of Harvard College to become the Prime Minister of Canada with two others in the role having received past master&#8217;s degrees from the prestigious American university.
While at Harvard from 1984 to 1988, Carney was a member of the university&#8217;s hockey team where he was a goalie.
&#8220;He was the best backup goalie Harvard ever had,&#8221; fellow Harvard student and Silver Lake co-founder Glenn Hutchins once said of Carney.
Carney also played goalie while at Oxford working on his doctorate, where he was a co-captain of the hockey team.
3.&nbsp;Bitcoin Stance:&nbsp;Fans of cryptocurrency and&nbsp;Bitcoin&nbsp;(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)&nbsp;in Canada may not want to hear about Carney&#8217;s past comments on the sector.
While Trump has ushered in a new cryptocurrency era in the U.S. with a pro-crypto agenda and plans for a&nbsp;<a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise" target="_blank" rel="noreferrer noopener">Bitcoin strategic reserve,</a>&nbsp;Carney might have to make a similar reversal of course to please Bitcoin fans.
Carney previously criticized Bitcoin for having &#8220;serious deficiencies&#8221; and said having a Bitcoin standard &#8220;would be a criminal act of monetary amnesia,&#8221; as reported by&nbsp;<a href="https://cointelegraph.com/news/canadas-new-prime-minister-mark-carney-bitcoin-critic" target="_blank" rel="noreferrer noopener">CoinTelegraph</a>.
The Canadian&#8217;s criticism of Bitcoin dates back to at least 2018 according to the report.
&#8220;The fixed supply of Bitcoin has fed a global speculative mania that has encouraged a proliferation of new cryptocurrencies,&#8221; Carney previously said.
Carney has spoken positively of CBDCs previously and said Bitcoin has proven to be &#8220;poor short-term stores of value.&#8221;
4. Board of Directors Roles:&nbsp;Along with roles at Goldman Sachs and the national banks getting Carney ready for his role as prime minister, the well-known banker also served on several notable boards.
With his push into politics, Carney has&nbsp;<a href="https://www.pionline.com/money-management/bank-canadas-mark-carney-resigns-asset-manager-boards-brookfield-pimco-he-enters" target="_blank" rel="noreferrer noopener">stepped&nbsp;</a>down from many of his board roles. Carney previously served on the board of directors of&nbsp;Brookfield Asset Management&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>), a unit of&nbsp;Brookfield Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>).
Carney also resigned from his role on the global advisory board of&nbsp;Pacific Investment Management Co, also known as&nbsp;PIMCO. Carney previously served on the board of directors of Bloomberg L.P. and<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44081480/stripes-payment-surge-puts-adyen-paypal-fiserv-on-notice-ai-stablecoins-fuel-the-race" target="_blank" rel="noreferrer noopener">&nbsp;fintech unicorn&nbsp;</a>Stripe, which was valued at $91.5 billion last month.
&#8220;I am no longer a senior executive at Brookfield, I am no longer a senior executive at Bloomberg, I am no longer on the board of Stripe, I am no longer on the board of PIMCO,&#8221; Carney said in an announcement ahead of his prime minister run.
Carney said the board roles and his banking experience will serve Canada well.
&#8220;What I&#8217;m bringing from those (experiences) is to help Canada through the immediate crisis, but really to build the strongest economy in the G7.&#8221;<a href="https://nypost.com/2025/03/08/world-news/mark-carney-frontrunner-to-replace-trudeau-as-canadas-pm/" target="_blank" rel="noreferrer noopener"></a>
5. Sports Fan/House Divided: A former hockey player, Carney is a <a href="https://www.telegraph.co.uk/finance/economics/9866686/Mark-Carney-is-an-Everton-fan...-but-his-wife-supports-Arsenal.html" target="_blank" rel="noreferrer noopener">fan </a>of the sport and the Edmonton Oilers are his favorite NHL team. Carney is also a fan of the Canadian Football League team Edmonton Eskimos.
Carney is also a fan of soccer and roots for Everton in the English Premier League, with distant relatives living in the Liverpool area. Carney&#8217;s wife Diana roots for Arsenal as her favorite soccer team, an Everton rival in the English Premier League. Diana, like Carney, also played hockey in college for the Oxford team.
The Canadian has also used the recent victory by Canada over the U.S. in the 4 Nations hockey tournament as a rallying cry ahead of the April election.
&#8220;Canada will not bow down to a bully. In the trade war — just like in hockey — we will win,&#8221; Carney said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44550892/canadian-pm-mark-carney-calls-first-trump-talk-constructive-amid-looming-tariff-threat">Canadian PM Mark Carney Calls First Trump Talk &#8216;Constructive&#8217; Amid Looming Tariff Threat</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Image: Shutterstock

Education

Global

$BTC

5 Things You Might Not Know About Canadian Prime Minister Mark Carney: From Playing College Hockey To Bitcoin

AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is trading higher Tuesday. The stock has been in an uptrend. In the past week, it has <a href="https://www.benzinga.com/25/04/45050728/abbvies-immunology-portfolio-poised-to-continue-growing-through-humira-erosion-analyst">gained more than 12%.</a>
But now it is overbought. This could draw sellers into the market and they could pressure AbbVie lower. Benzinga&#8217;s team of technical analysts has made it the Stock of the Day.
Overbought refers to the momentum of a stock. Most of the time it will stay in its normal or average trading range. If it is aggressively bought and gets above this range, traders will say that it is overbought.
This could be an important dynamic.
Many trading strategies are based on the concept of reversion to the mean. If something is overbought, this would mean a move lower. Some traders will sell AbbVie in anticipation of this move.
This could put it into a downtrend.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">How You&#8217;ll Know When Tariff Troubles Are Finally Over</a>
The bottom part of the chart has two examples of the Relative Strength Index (RSI). It is a popular indicator that is used to analyze momentum.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-1024x566.png" alt="" class="wp-image-893227" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/29110708/ABBV.png 1488w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
The default time period that is used is 14. This measures where the price is now versus where it was 14 days ago. It doesn't account for moves that took place in between these periods.
The 14-day momentum is neutral—today's price is roughly the same as two weeks ago, so it hasn't yet registered the recent rally.
If the time-period setting is changed from 14 to 5, it shows the shares to be very overbought.
Most indicators that traders use come with preset default settings. Sometimes, these can give good signals.
But sometimes, the indicators can be optimized by using different settings. Considering recent market conditions, in the case of AbbVie, a 5-day RSI may be more effective than a 14-day one.
The rally may pause or even end.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a></li>
</ul>
Photo: Shutterstock

Technicals

ABBV

Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next?

Guggenheim analyst Kelsey Goodwin reiterates UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) from Buy to Buy.

Reiteration

Analyst Ratings

URGN

Guggenheim Reiterates Buy on UroGen Pharmato Buy

Shares of Odyssey Marine Exploration Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) have surged 225% to $1.4 over the past week as investors continue to react to a policy shift by the U.S. government. The rally follows President Donald Trump&#8217;s <a href="https://www.benzinga.com/government/regulations/25/04/45005308/sea-mining-stocks-soar-as-trump-signs-executive-order-to-jumpstart-sector">executive order</a> aimed at jumpstarting the domestic deep-sea mining industry.
What To Know: The order directs federal agencies to streamline permits for seabed mineral extraction on the U.S. Outer Continental Shelf and in <a href="https://www.benzinga.com/25/04/45016230/odyssey-marine-exploration-stock-surges-on-continued-momentum-whats-going-on">international waters</a> under the 1980 Deep Seabed Hard Mineral Resources Act.
Based in Florida, Odyssey Marine is one of the few publicly traded U.S. companies with proprietary technology and expertise in deep-ocean mineral exploration. With projects in Mexico and the South Pacific long stalled by regulatory hurdles, the new directive could be seen as a game-changer.
By allowing companies to apply for permits directly through the National Oceanic and Atmospheric Administration, the U.S. bypasses the slower, UN-affiliated International Seabed Authority.
As demand for critical minerals like nickel, copper, and rare earths rises, the market may view Odyssey as a prime beneficiary of this domestic-first approach to resource development.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a>
<h2 class="wp-block-heading">How To Buy OMEX Stock</h2>
By now you're likely curious about how to participate in the market for Odyssey Marine &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Odyssey Marine, which is trading at $1.49 as of publishing time, $100 would buy you 67.11 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, OMEX has a 52-week high of $5.57 and a 52-week low of $0.27.

OMEX

Odyssey Marine Exploration (OMEX) Soars 225% Amid US Deep-Sea Mining Policy Shift

Guggenheim analyst Jason Cassorla reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Neutral.

Guggenheim Reiterates Neutral on Centeneto Neutral

JP Morgan analyst Ken Worthington maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Neutral and lowers the price target from $176 to $167.

Price Target

HLNE

JP Morgan Maintains Neutral on Hamilton Lane, Lowers Price Target to $167

<a href="https://news.delta.com/delta-raise-employee-pay-fourth-consecutive-year">https://news.delta.com/delta-raise-employee-pay-fourth-consecutive-year</a>

Delta Air Lines Plans To Provide A 4% Pay Raise To Eligible Employees Worldwide

JP Morgan analyst Peter Peng maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Overweight and lowers the price target from $30 to $25.

AMKR

JP Morgan Maintains Overweight on Amkor Tech, Lowers Price Target to $25

<a href="https://about.fb.com/news/2025/04/introducing-meta-ai-app-new-way-access-ai-assistant/">https://about.fb.com/news/2025/04/introducing-meta-ai-app-new-way-access-ai-assistant/</a>

'Introducing the Meta AI App: A New Way to Access Your AI Assistant' -Facebook

JP Morgan analyst Stephen Tusa maintains Roper Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) with a Neutral and raises the price target from $465 to $470.

JP Morgan Maintains Neutral on Roper Technologies, Raises Price Target to $470

Markel Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKL#NYSE">MKL</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Markel Group will report an earnings per share (EPS) of $17.97.
Markel Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $19.74, leading to a 10.74% increase in the share price on the subsequent day.
Here's a look at Markel Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>19</td>
<td>21.43</td>
<td>21.30</td>
<td>24.86</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>38.74</td>
<td>66.25</td>
<td>18.62</td>
<td>75.43</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.0%</td>
<td>-2.0%</td>
<td>-4.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745938972_0.png" alt="eps graph" />
<h3>Tracking Markel Group's Stock Performance</h3>
Shares of Markel Group were trading at $1813.28 as of April 28. Over the last 52-week period, shares are up 22.15%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/MKL/earnings">To track all earnings releases for Markel Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Markel Group's Earnings: A Preview

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) is preparing to release its quarterly earnings on Wednesday, 2025-04-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Morningstar to report an earnings per share (EPS) of $2.06.
Investors in Morningstar are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.08, which was followed by a 2.75% drop in the share price the next day.
Here's a look at Morningstar's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.06</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.14</td>
<td>2</td>
<td>2.01</td>
<td>1.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>6.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Morningstar were trading at $278.74 as of April 28. Over the last 52-week period, shares are down 2.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Morningstar</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Morningstar.
With 1 analyst ratings, Morningstar has a consensus rating of Outperform. The average one-year price target is $370.0, indicating a potential 32.74% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of MarketAxess Holdings, FactSet Research Systems and Donnelley Financial Solns, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for MarketAxess Holdings, with an average 1-year price target of $237.0, suggesting a potential 14.97% downside.</li>
<li>Analysts currently favor an Neutral trajectory for FactSet Research Systems, with an average 1-year price target of $455.86, suggesting a potential 63.54% upside.</li>
<li>Analysts currently favor an Buy trajectory for Donnelley Financial Solns, with an average 1-year price target of $70.4, suggesting a potential 74.74% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary presents essential metrics for MarketAxess Holdings, FactSet Research Systems and Donnelley Financial Solns, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morningstar</td>
<td>Outperform</td>
<td>9.71%</td>
<td>$358.80M</td>
<td>7.34%</td>
</tr>
<tr>
<td>MarketAxess Holdings</td>
<td>Neutral</td>
<td>2.61%</td>
<td>$138.57M</td>
<td>4.69%</td>
</tr>
<tr>
<td>FactSet Research Systems</td>
<td>Neutral</td>
<td>4.53%</td>
<td>$301.06M</td>
<td>7.16%</td>
</tr>
<tr>
<td>Donnelley Financial Solns</td>
<td>Buy</td>
<td>-11.44%</td>
<td>$93.70M</td>
<td>1.43%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Morningstar outperforms peers in revenue growth, ranking at the top with 9.71%. In terms of gross profit, Morningstar leads with $358.80M. Additionally, Morningstar has the highest return on equity at 7.34%.
<h3>Delving into Morningstar's Background</h3>
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.
<h3>Morningstar: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Morningstar's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 9.71%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Morningstar's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 19.78%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Morningstar's ROE excels beyond industry benchmarks, reaching 7.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.29%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.56, Morningstar adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/MORN/earnings">To track all earnings releases for Morningstar visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

Earnings Preview For Morningstar

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.
Analysts estimate that MetLife will report an earnings per share (EPS) of $2.00. 
Anticipation surrounds MetLife's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 1.56% drop in the share price on the following day.
Here's a look at MetLife's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.09</td>
<td>2.17</td>
<td>2.17</td>
<td>1.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.09</td>
<td>1.95</td>
<td>2.28</td>
<td>1.83</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-6.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745938954_0.png" alt="eps graph" />
<h3>Tracking MetLife's Stock Performance</h3>
Shares of MetLife were trading at $75.94 as of April 28. Over the last 52-week period, shares are up 5.51%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MET/earnings">To track all earnings releases for MetLife visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MetLife's Earnings Outlook

<a href="https://www.globenewswire.com/Tracker?data=xTqV-GYC_7VTanMIMztvZwe3hwtcN3g_Rabet0SlO41HQrmxeV68b9ybd8m8Mvf4lr6YZ5s8YCzrylT8Xsc9sq-T9GRLxlgWyYWTI4StOgM=">MasterCraft Boat Company</a>, a subsidiary of MasterCraft Boat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) and the best-selling towboat brand, today announces a new dealership partnership with <a href="https://www.globenewswire.com/Tracker?data=MMclgeb10fJC3WyQ5XBZEXDKAkLM2mZggfnZjEhmum-JfMD5DD0OA4n4lHhB1EXsooPzp1pVoxN-P37saLsFnivuICzJCI-iDKKTD546oSr7nWU4GWQhxqXAnnC_Pw6h">Performance Marine Watersports</a>, a trusted name in Osage Beach, MO, for over 30 years. This strategic expansion further positions MasterCraft as a leader in the towboat category and throughout the Lake of the Ozarks region, combining its award-winning innovation and craftsmanship with Performance Marine Watersports' proven expertise and dedication to exceptional customer service. Through this partnership, MasterCraft's reinforces its commitment to delivering best-in-class experiences for current and future MasterCraft owners.

MCFT

MasterCraft Boat Announces New Dealership Partnership With Performance Marine Watersports

Press Releases

Shareholders of Treace Medical Concepts, Inc. Should Contact Levi & Korsinsky Before June 10, 2025 to Discuss Your Rights - TMCI

TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit

Legal

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical

The Gross Law Firm Reminds Treace Medical Concepts, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 10, 2025 - TMCI

TREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming Deadline

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit – TMCI

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCI

Levi & Korsinsky Reminds Treace Medical Concepts, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 10, 2025 - TMCI

Comments

Treace Medical Concepts

Treace Medical Concepts (TMCI) オプション

Treace Medical Concepts (NASDAQ:TMCI) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル